secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0000950170-24-012186
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q1 revenue $18M, net loss $33.4M; RSV data expected Q3 2024
------------------------------------------------------------------

- Revenue $18.0M (down from $23.6M YoY) from AbbVie's MAVYRET royalties; net loss $33.4M ($1.58/share) vs $29.0M loss YoY.
- Cash and marketable securities $337.2M; expected to fund operations through fiscal 2027.
- Anticipates topline data from RSVPEDs Phase 2 study of zelicapavir and EDP-323 Phase 2a challenge study in Q3 2024.
- Expanded into immunology with oral KIT inhibitor program for chronic spontaneous urticaria; development candidate selection targeted for 2024.
- G&A expenses rose to $16.5M due to legal fees from patent infringement suit against Pfizer and higher stock compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017024012186/0000950170-24-012186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017024012186/enta-20240207.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-012186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer